Other JAK inhibitors in earlier stages of research in AD are abrocitinib (PF-04965842), a JAK1 inhibitor, and gusacitinib (ASN002) and cerdulatinib (RVT-502), inhibitors of both JAK and spleen tyrosine kinase (SYK) pathways. The gene discussed is JAK1; the disease is Alzheimer disease.